If you have been reading about cyclic heptapeptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | No marketing authorization in major jurisdictions |
| Scheduling example | Prescription-only supply in some countries | Handled as an unlicensed medicine where restricted |
| Sports classification | Prohibited peptide | Appears on anti-doping prohibited lists |
| Reported presentation | Lyophilized vial | Nominal content varies between vendors |
| Detection approach | Liquid chromatography–tandem mass spectrometry | Used in anti-doping and forensic testing |
Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
Reversed-phase high-performance liquid chromatography is the routine method for purity assessment. Peptides absorb near 214 nm because of the peptide bond, and a gradient of acetonitrile in water separates the intact peptide from deletion sequences, oxidised products, and earlier-eluting fragments at neutral pH. Electrospray ionisation mass spectrometry provides an orthogonal check: the measured mass must agree with the theoretical value. Amino acid analysis and peptide mapping confirm structure but are used less often. Reference standards remain scarce because the peptide is not described in any pharmacopoeia.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Melanotan-2 appears on the World Anti-Doping Agency prohibited list within the peptide hormone class, and several national regulators treat it as an unapproved prescription substance. Some countries restrict importation or sale for personal use. Because the compound is widely traded as a research chemical, the practical legal picture differs between jurisdictions and shifts over time. Human safety data covering long periods are limited, and whether repeated pigmentation changes carry any lasting risk to melanocytes remains an open question.
Freeze-dried melanotan-2 is normally kept as a desiccated powder at minus twenty degrees Celsius or lower, shielded from light and moisture. Peptides of this size degrade through hydrolysis, oxidation and deamidation, and each pathway accelerates as temperature and water activity rise. Repeated freeze-thaw cycles promote aggregation and loss of material, so aliquoting a stock solution before freezing is standard laboratory practice. Once dissolved, the solution is markedly less stable than the powder. In laboratory work, solutions are generally refrigerated and used within days rather than kept for months.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or oxidised impurities. Mass spectrometry, most often coupled to liquid chromatography, confirms molecular mass and detects substitutions that chromatography alone may miss. Amino acid analysis and peptide mapping supply additional structural evidence, while nuclear magnetic resonance is reserved for full structural confirmation. Laboratories that examine samples sold online report wide variation in actual content, with some vials containing little or none of the labelled material.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
=== Journal articles and book chapters === Humphreys, Laud. (1970). "Impersonal sex in public places." Transaction, January, 1970: 10–25. Humphreys, Laud. (1971). "New styles in homosexual manliness." Transaction, March/April 1971: 38–46, 64–65. Humphreys, Laud. (1974). "Homosexual exchanges in public places." pp. 129–142 in L. Rainwater (ed.), Social problems and public policy: Deviance and liberty. Hawthorne, NY: Aldine. Humphreys, Laud. (1975). "Predicting the unpredictable: Some crime prospects for the decade." The Participant, Winter. Humphreys, Laud. (1978). "An interview with Evelyn Hooker." Alternative lifestyles: Changing patterns in marriage, family, & intimacy, Vol. 1, No. 2. Humphreys, Laud. (1979). "Being odd against all odds." pp. 238–242 in R. Fedarico (ed.), Sociology (2nd edition). Reading, MA: Addison-Wesley. Humphreys, Laud. (1979). "Exodus and identity: The emerging gay culture." pp. 134–147 in M. Levine (ed.), Gay men: The sociology of male homosexuality. New York: Harper and Row. Humphreys, Laud. (1980). "Homosexuality in perspective." Society 17(6): 84–86. Humphreys, Laud; Miller, Brian. (1980). "Keeping in touch: Maintaining contact with stigmatized subjects." pp. 212–223 in W. Shaffir, R. Stebbins, and A. Turowetz (eds.), Field Work Experience: Qualitative Approaches to Social Research. New York: St. Martin's Press. Miller, Brian; Humphreys, Laud. (1980). "Lifestyles and violence: Homosexual victims of assault and murder." Qualitative Sociology 3(3): 169–185. Goodwin, Glenn A; Humphreys, Laud. (1982).
== Pro-Soviet accounts == Soviet historiography on the Cold War era was overwhelmingly dictated by the Soviet state, and blamed the West for the Cold War. In Britain, the historian E. H. Carr wrote a 14-volume history of the Soviet Union, which was focused on the 1920s and published 1950–1978. His friend R. W. Davies said Carr belonged to the anti-Cold War school of history, which regarded the Soviet Union as the major progressive force in the world, the United States as the world's principal obstacle to the advancement of humanity and the Cold War as a case of American aggression against the Soviet Union. Carr criticized those Anglophone historians, who he felt had unfairly judged the Soviet Union by the cultural norms of Britain and the United States.
== Associated disorders == The most common associated disorder is pre-eclampsia, affecting approximately 7% of all births. It is characterized by a failure of the cytotrophoblast to invade the uterus and its vasculature, specifically the spiral arteries that the endovascular cytotrophoblast should invade. The result of this is decreased blood flow to the fetus which may cause intrauterine growth restriction. Clinical symptoms of pre-eclampsia in the mother are most commonly high blood pressure, proteinuria and edema. Conversely, if there is too much invasion of uterine tissue by the trophoblast then a hydatidiform mole or choriocarcinoma may arise.
Portal began with the 2005 freeware game Narbacular Drop, developed by students of the DigiPen Institute of Technology. Robin Walker, one of Valve's developers, saw the game at the DigiPen's career fair. Impressed, he contacted the team with advice and offered to show Narbacular Drop at Valve's offices. After their presentation, Valve's president Gabe Newell offered the team jobs at Valve to develop it further. Newell said he was impressed with the team as "they had actually carried the concept through", already having included the interaction between portals and physics, completing most of the work that Valve would have had to commit on their own. To test the effectiveness of the portal mechanic, the team made a prototype in an in-house 2D game engine that is used in DigiPen. Certain elements were retained from Narbacular Drop, such as the system of identifying the two unique portal endpoints with the colors orange and blue. A key difference is that Portal's portal gun cannot create a portal through an existing portal, unlike in Narbacular Drop. The original setting, of a princess trying to escape a dungeon, was dropped in favor of the Aperture Science approach. Portal took approximately two years and four months to complete after the DigiPen team was brought into Valve, and no more than ten people were involved with its development.
=== Fat distribution === In hormone therapy, trans women often experience slight weight gain as men generally carry higher levels of visceral fat compared to subcutaneous fat, and less fat overall compared to women. Over months and years, HRT causes the body to accumulate new fat in a feminine pattern (gynoid fat). Unlike abdominal fat, gynoid fat has little effect on overall health except in the case of severe excess or postural changes. Gynoid fat will accumulate in the hips, lower belly, thighs, buttocks, pubis, upper arms, and breasts while the body burns fat in the ribcage, upper waist, shoulders, and back. However, fat will not simply move from one spot to another. There must be sufficient caloric intake to deposit gynoid fat, and sufficient activity to burn android fat.
Sources: en.wikipedia.org
Geraniol 8-hydroxylase is a cytochrome P450 protein containing heme. It requires a partner cytochrome P450 reductase for functional expression. This uses nicotinamide adenine dinucleotide phosphate (NADPH).
The benefits of beak trimming are mainly welfare advantages for birds kept in close confinement, some of which directly relate to increases (or reduced decreases) in production. These include reduced feather pecking and cannibalism, better feathering (though they find it hard to preen with shortened beaks, which means they are not cleaning themselves well), less fearfulness and nervousness, less chronic stress, and decreased mortality.
In France, the National Museum of Natural History (French: Muséum national d'histoire naturelle [myzeɔm nɑsjɔnal distwaʁ natyʁɛl]; MNHN) is the national natural history museum of France and a grand établissement of higher education part of Sorbonne University. The main museum, with four galleries, is located in Paris, France, within the Jardin des Plantes on the left bank of the River Seine. It was formally founded in 1793, during the French Revolution, but was begun even earlier in 1635 as the royal garden of medicinal plants. The MNHN now has 14 sites throughout France. Since the 2014 reform, it has been headed by a chairman, assisted by deputy managing directors. The Museum has a staff of approximately 2,350 members, including six hundred researchers. It is a member of the national network of naturalist collections (RECOLNAT).
Amylin, or islet amyloid polypeptide (IAPP), is a 37-residue peptide hormone. It is co-secreted with insulin from the pancreatic β-cells in the ratio of approximately 100:1 (insulin:amylin). Amylin plays a role in glycemic regulation by slowing gastric emptying and promoting satiety, thereby preventing spikes in blood glucose levels after a meal. IAPP is processed from an 89-residue coding sequence. Proislet amyloid polypeptide (proIAPP, proamylin, proislet protein) is produced in the pancreatic beta cells (β-cells) as a 67 amino acid, 7404 Dalton pro-peptide and undergoes post-translational modifications including protease cleavage to produce amylin.
Insoluble accumulations of β-amyloid peptide in brain regions related to memory and cognition are a defining characteristic of Alzheimer's disease (AD). SNX8 has a neuroprotective role related to AD: it enhances the non-amyloidogenic APP pathway and, hence, reduces the Aβ plaques and deposit accumulations and suppresses cognitive impairment caused by AD. Some studies found that SNX8 levels were drastically lower in patients with AD. Furthermore, it has been demonstrated that SNX8 overexpression mediated by adeno-associated virus (AVV) reduced Aβ levels and reversed cognitive impairment in AD mice. It is also important mentioning that a pair of polymorphisms (rs2286206 and rs10249052) within the human SNX8 gene locus have also been associated with late-onset AD.
Sources: en.wikipedia.org
Femarelle is a dietary supplement range containing DT56a, a tofu-derived soy extract, together with additional ingredients including flaxseed powder, vitamins, and minerals. DT56a has been studied for its potential activity as a selective estrogen receptor modulator (SERM), meaning that it may interact selectively with estrogen receptors in different tissues. Femarelle has been evaluated in several clinical studies investigating its possible role in supporting women during menopause, including studies on menopausal symptoms, vaginal health, bone health, and safety profile. Some studies reported encouraging findings, including improvements in menopausal symptoms and a favorable safety profile compared with traditional hormone replacement therapy, although the published trials were generally limited by relatively small sample sizes and short study durations. In 2008, an application was submitted to the European Food Safety Authority (EFSA) regarding a health claim related to bone mineral density and osteoporosis risk. EFSA concluded that the available evidence at that time was insufficient to establish a cause-and-effect relationship between Femarelle consumption and improvements in bone mineral density or reduction of osteoporosis risk in postmenopausal women.
== In nuclear power reactors == In any operating nuclear reactor containing 238U, some plutonium-239 will accumulate in the nuclear fuel. Unlike reactors used to produce weapons-grade plutonium, commercial nuclear power reactors typically operate at a high burnup that allows a significant amount of plutonium to build up in irradiated reactor fuel. Plutonium-239 will be present both in the reactor core during operation and in spent nuclear fuel that has been removed from the reactor at the end of the fuel assembly's service life (typically several years). Spent nuclear fuel commonly contains about 0.8% plutonium-239. Plutonium-239 present in reactor fuel can absorb neutrons and fission just as uranium-235 can. Since plutonium-239 is constantly being created in the reactor core during operation, the use of plutonium-239 as nuclear fuel in power plants can occur without reprocessing of spent fuel; the plutonium-239 is fissioned in the same fuel rods in which it is produced. Fissioning of plutonium-239 provides more than one-third of the total energy produced in a typical commercial nuclear power plant. Reactor fuel would accumulate much more than 0.8% plutonium-239 during its service life if some plutonium-239 were not constantly being "burned off" by fissioning. A small percentage of plutonium-239 can be deliberately added to fresh nuclear fuel. Such fuel is called MOX (mixed oxide) fuel, as it contains a mixture of uranium dioxide (UO2) and plutonium dioxide (PuO2). The addition of plutonium-239 reduces the need to enrich the uranium in the fuel.
Promising results of health and medical research are reported: non-human vaccinated primates-tested pGal–antigen therapy for suppressing antigen-specific immune responses and against autoimmune diseases, this type of vaccine is called "inverse vaccine" (7 Sep), 3D cell-culture tested exercise-induced hormone irisin against Aβ Alzheimer's disease pathology (8 Sep), identified diverse features strongly associated with long COVID for better diagnosis (25 Sep). Promising innovations relating to global challenges are reported: a study winning an international competition demonstrates an approach that predicted 70% of earthquakes, suggesting some form of earthquake prediction may be feasible in the future (5 Sep), researchers release a large set of audiobooks for books in Project Gutenberg created automatically via generative AI with near-natural voice (7 Sep), a news outlet reports on a natural language system, demonstrated on 27 July, that can provide explanations for the conclusion-making of machine learning models for explainable AI (12 Sep), researchers report a production method for spider silk fibers from gene-edited transgenic silkworms for a sustainable alternative material six times stronger than Kevlar (20 Sep), a new generation of sleeping trains is presented amid a comeback of this transport technology in Europe as demand for more comfortable travel modes than overnight buses and sustainable transport rises (30 Sep).
=== Cephalopods === Architeuthis dux, giant squid (2020) Euprymna scolopes, Hawaiian bobtail squid (2019) Hapalochlaena maculosa, Southern blue-ringed octopus (2020) Octopus bimaculoides, California two-spot octopus (2015) Octopus minor, common long-arm octopus (2018) Octopus vulgaris, common octopus (2019)
=== Trials of drugs === Some clinical trials involve healthy subjects with no pre-existing medical conditions. Other clinical trials pertain to people with specific health conditions who are willing to try an experimental treatment. Pilot experiments are conducted to gain insights for design of the clinical trial to follow. There are two goals to testing medical treatments: to learn whether they work well enough, called "efficacy", or "effectiveness"; and to learn whether they are safe enough, called "safety". Neither is an absolute criterion; both safety and efficacy are evaluated relative to how the treatment is intended to be used, what other treatments are available, and the severity of the disease or condition. The benefits must outweigh the risks. For example, many drugs to treat cancer have severe side effects that would not be acceptable for an over-the-counter pain medication, yet the cancer drugs have been approved since they are used under a physician's care and are used for a life-threatening condition. In the US the elderly constitute 14% of the population, while they consume over one-third of drugs. People over 55 (or a similar cutoff age) are often excluded from trials because their greater health issues and drug use complicate data interpretation, and because they have different physiological capacity than younger people. Children and people with unrelated medical conditions are also frequently excluded. Pregnant women are often excluded due to potential risks to the fetus.
Sources: en.wikipedia.org
Only a small number of early-stage human studies have been reported, and most were limited in size and duration. No large late-stage program has established a general efficacy or safety profile. The evidence base is therefore thin compared with approved medicines.
The peptide is listed as prohibited in competitive sport, so laboratories develop detection methods and monitor for its presence. Its appearance in enforcement reports reflects that classification rather than any approved athletic use. Analytical work in this area focuses on identifying the molecule and its breakdown products in biological samples.
Chromatographic separation combined with mass spectrometry identifies the peptide and estimates its amount in a sample. Testing can confirm whether the expected molecule is present and at what concentration. It cannot establish how a product was manufactured or whether it meets any purity standard.
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.